The FDA approved Lumipulse G, a blood test that detects P-Tau217, a protein that signals Alzheimer's risk before symptoms show. Bryan Johnson's P-Tau217 level dropped 28% after hyperbaric oxygen therapy, suggesting the biomarker can change with intervention.
I had a marker for cognitive decline, and I reversed it. The FDA just approved a blood test that can spot signs of Alzheimer's before the symptoms emerge. It's called lumipulse G, and it identifies a protein in your blood called P Tau217. When this protein builds up, it's a sign your brain could be in trouble later. I took the test a few months ago, and My level was 0.14. With that as my baseline, I started a therapy called hyperbaric oxygen therapy, and it lowered my levels by 28%. As I've learned over the years, measurement is king. I no longer A lot of you are scared of data and knowing, but honestly, it's the best thing for your health. Measure yourself, learn your risks, and take the appropriate actions.
